SEC Form 4 · accession 0001104659-18-073103
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Yancopoulos
Officer — President and CSO · Director
Period of report
Nov 2, 2015
Accepted (ET)
Dec 14, 2018 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2015 | G | 43,348 | $0.00 | D | 500,000 | D | |
| Common Stock | Dec 17, 2015 | G | 1,921 | $0.00 | D | 500,000 | D | |
| Common Stock | Dec 16, 2016 | G | 89,427 | $0.00 | D | 500,000 | D | |
| Common Stock | Dec 14, 2017 | G | 89,264 | $0.00 | D | 500,847 | D | |
| Common Stock | Dec 19, 2017 | G | 242,150 | $0.00 | D | 847 | D | |
| Common Stock | Aug 21, 2018 | G | 847 | $0.00 | D | 0 | D | |
| Common Stock | Jul 21, 2017 | G | 176,223 | $0.00 | D | 323,777 | I | By 2016 GRAT |
| Common Stock | Jul 24, 2018 | G | 299,134 | $0.00 | D | 24,643 | I | By 2016 GRAT |
| Common Stock | Nov 1, 2018 | G | 24,643 | $0.00 | D | 0 | I | By 2016 GRAT |
| Common Stock | Aug 3, 2017 | G | 176,223 | $0.00 | A | 176,223 | I | By 2017 GRAT |
| Common Stock | Aug 3, 2018 | G | 101,187 | $0.00 | D | 75,036 | I | By 2017 GRAT |
| Common Stock | Nov 2, 2015 | G | 43,348 | $0.00 | A | 612,936 | I | By Trust |
| Common Stock | Dec 17, 2015 | G | 1,921 | $0.00 | A | 569,897 | I | By Trust |
| Common Stock | Dec 16, 2016 | G | 89,427 | $0.00 | A | 159,324 | I | By Trust |
| Common Stock | Jul 21, 2017 | G | 176,223 | $0.00 | A | 331,629 | I | By Trust |
| Common Stock | Aug 3, 2017 | G | 176,223 | $0.00 | D | 155,406 | I | By Trust |
| Common Stock | Dec 14, 2017 | G | 89,264 | $0.00 | A | 244,670 | I | By Trust |
| Common Stock | Dec 19, 2017 | G | 242,150 | $0.00 | A | 486,820 | I | By Trust |
| Common Stock | Feb 16, 2018 | G | 400,000 | $0.00 | D | 86,820 | I | By Trust |
| Common Stock | Jul 24, 2018 | G | 299,134 | $0.00 | A | 385,954 | I | By Trust |
| Common Stock | Aug 3, 2018 | G | 101,187 | $0.00 | A | 487,141 | I | By Trust |
| Common Stock | Aug 21, 2018 | G | 847 | $0.00 | A | 487,988 | I | By Trust |
| Common Stock | Aug 22, 2018 | G | 3,211 | $0.00 | D | 484,777 | I | By Trust |
| Common Stock | Nov 16, 2018 | G | 1,176 | $0.00 | D | 483,601 | I | By Trust |
| Common Stock | Feb 16, 2018 | G | 400,000 | $0.00 | A | 400,000 | I | By 2018 GRAT |
| Common Stock | holding | — | — | — | 5,728 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $381.40 | Dec 12, 2018 | A | 129,013 | A | — | Dec 12, 2028 | Common Stock | 129,013 | 129,013 | D |
Explanation of responses
- F1The stock option award vests in four equal annual installments, commencing one year after the date of grant.